Volastra Therapeutics, Inc. is a biotechnology company based in New York City, formed from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum. Volastra is dedicated to the discovery and development of treatments for patients with cancer. The Company’s therapies will target novel pathways and apply insights gained from its scientific founders into chromosomal instability (CIN) and its clear association with the formation, progression, and maintenance of disease. Leveraging these insights we will identify and quickly validate novel therapies to shift the treatment paradigm in the toughest to treat cancers.
Volastra has raised $45M in funding from top US and European venture firms, including Vida, Polaris, Droia, and Arch. Current funding will look to advance a lead program into the clinic, advance another program to IND-enabling studies and strengthen the platform to identify a broader pipeline of candidates. The company has a world class scientific advisory board including two Nobel Laureates as well as a highly experienced senior leadership team. This includes the CEO, CSO and senior leaders with expertise in chemistry, biochemistry, biology, immunology, and operations.
The company operates out of 15,000 square feet of office and state-of-the-art laboratory space in West Harlem, New York City, within easy traveling distance of Columbia, Cornell, Memorial Sloan Kettering, and all most other areas of the city and New Jersey.
Please visit www.volastratx.com for more information
Volastra is seeking a highly motivated Senior Research Associate/Scientist I, Tumor Immunology for an in vitro and in vivo biology lab-based role. The person who fills this position will report to the Director of Immunology and work closely with the scientific team to achieve the company’s scientific and strategic plan. The Scientist will be responsible for validating novel targets and ensuring the advancement of key drug development programs in the Volastra pipeline as part of the larger scientific team. The ideal candidate should be someone who takes initiative, is a team player and an independent thinker, and has excellent analytical and communication skills. Additionally, the candidate should have a good publication track record in peer-reviewed journals, experience developing and implementing in vitro, in vivo and ex vivo immunological assays and expertise characterizing mechanisms of anti-tumor immunity in syngeneic tumor models.
Project responsibilities will include, but are not limited to:
- Validate novel immune-oncology targets identified through the company’s CIN/metastasis platform
- Develop, validate and execute in vitro, ex vivo, and in vivo immunological experiments
- Interrogate the biology of CIN and metastasis to yield new mechanistic insights
- Experience developing co-culture assays
- Experience with genetic manipulation (overexpression, RNAi and/or CRISPR/Cas9) of primary immune cells and cancer cells
- Experience with bioluminescent in vivo imaging to study metastasis
- Benchling inventory/registry/ELN system